[AGN] Allergan plc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 96.6 B

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 198.87 Change: 4.89 (2.52%)
Ext. hours: Change: 0 (0%)

chart AGN

Refresh chart

Strongest Trends Summary For AGN

AGN is in the long-term up 591% in 19 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding395.56 M EPS EPS Growth - 4 Quarters115.47% EPS Growth - Q/Q75.5%
EPS Growth - Y/Y58.22% Sales Growth - 4 Quarters 16.06% Sales Growth - Q/Q5.14% P/E
P/E To EPS Growth0.57 P/S13.35 P/BV12.46 Price/Cash Per Share19.45
Price/Free Cash Flow57.37 ROA12.28% ROE19.66% ROI14.05%
Current Ratio4.41 Quick Ratio4.22 Long Term Debt/Equity0.39 Debt Ratio0.2
Gross Margin88.36% Operating Margin27.76% Net Profit Margin21.06% Dividend Payout Ratio-3.91%
Dividend Yield-0.06%
Fundamental Data
Cash From Financing Activities Cash From Investing Activities183.4 M Cash From Operating Activities144.6 M Gross Profit1.7 B
Net Profit694.2 M Operating Profit626.7 M Total Assets12.42 B Total Current Assets6.87 B
Total Current Liabilities1.56 B Total Debt2.09 B Total Liabilities4.66 B Total Revenue1.91 B
Technical Data
High 52 week254.35 Low 52 week163.58 Last close181.33 Last change0.94%
RSI76.15 Average true range4 Beta0.66 Volume3.21 M
Simple moving average 20 days5.72% Simple moving average 50 days5.79% Simple moving average 200 days-14.33%
Performance Data
Performance Week2.38% Performance Month6.1% Performance Quart-2.72% Performance Half-26.68%
Performance Year-14.39% Performance Year-to-date10.85% Volatility daily1.51% Volatility weekly3.37%
Volatility monthly6.91% Volatility yearly23.95% Relative Volume226.12% Average Volume3.42 M
New High New Low


2019-11-12 17:12:59 | AbbVie Sells $30 Billion of Bonds to Fund Allergan Acquisition

2019-11-12 14:08:07 | Top Stock Reports for Booking Holdings, Allergan & Honda Motor Co.

2019-11-12 06:46:13 | AbbVie sells $30bn of bonds to finance Allergan takeover

2019-11-12 05:00:00 | AbbVie Eyes Up to $28 Billion Bond Sale to Finance Allergan Deal: Report

2019-11-11 17:13:38 | Allergan CEO on Innovation and Blockbuster Biopharmaceuticals

2019-11-11 10:32:03 | The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

2019-11-11 07:30:00 | Allergan Receives FDA Qualified Infectious Disease Product QIDP Designation And Fast Track Designation For ATM-AVI Aztreonam And Avibactam For Antibiotic-Resistant Gram-Negative Infections

2019-11-08 17:48:00 | Patients Sue Breast-Implant Manufacturer Allergan, Says Consumer-Rights Law Firm FeganScott

2019-11-08 09:59:02 | Teva TEVA Q3 Earnings Miss, Stock Up on Guidance Increase

2019-11-08 09:38:08 | With a Deal in Hand, Teva Stock Can Chart a Difficult Comeback

2019-11-08 09:26:02 | Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products

2019-11-07 10:51:03 | Aerie AERI Q3 Loss Wider, Sales Beat, Guidance Slashed

2019-11-07 10:18:09 | AbbVie Inc. -- Moody's assigns Baa2 to AbbVie's new sr. notes; stable outlook

2019-11-05 18:16:26 | Vanguard Health Care Fund Sells Out of Allergan

2019-11-05 15:57:07 | 2 Stocks to Watch Tuesday

2019-11-05 11:02:04 | Allergan AGN Meets Q3 Earnings Estimates, Ups '19 Sales View

2019-11-05 10:48:59 | Allergan's Q3 Sales Get A Facelift From Botox; AbbVie Deal On Track

2019-11-05 08:15:01 | Allergan AGN Q3 Earnings Meet Estimates

2019-11-05 07:38:00 | Allergan's stock gains after adjusted profit, revenue beat expectations

2019-11-05 07:00:00 | Allergan Reports Third Quarter 2019 Financial Results

2019-11-05 04:40:00 | [video]Allergan Tops Q3 Earnings, Bumps 2019 Sales Guidance Amid AbbVie Takeover

2019-11-04 13:08:56 | Allergan Q3 Earnings Preview

2019-11-04 12:28:00 | Marine algae keys Chinese claim to Alzheimer’s breakthrough

2019-11-04 12:27:00 | Day Ahead: Top 3 Things to Watch

2019-11-04 11:23:04 | Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More

2019-11-04 10:00:03 | Should You Buy Allergan AGN Ahead of Earnings?

2019-11-04 09:15:02 | Allergan AGN Hits 52-Week High, Can the Run Continue?

2019-11-01 16:21:10 | AbbVie Stock Jumps On Strong Quarter As Allergan Takeover Looms

2019-11-01 14:47:06 | AbbVie ABBV Beats on Q3 Earnings & Sales, Tweaks EPS View

2019-11-01 11:07:03 | WIll Allergan AGN Beat Estimates This Earnings Season?

2019-11-01 11:05:03 | Is a Beat in the Cards for Mallinckrodt MNK in Q3 Earnings?

2019-11-01 10:52:02 | Ironwood IRWD Beats on Q3 Earnings & Revenues, Ups '19 View

2019-11-01 10:10:07 | AbbVie says multiple parties vying for assets related to Allergan deal approval

2019-11-01 09:04:00 | AbbVie Delivers on Earnings and Raises Forecast

2019-11-01 08:46:39 | UPDATE 2-AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales

2019-11-01 08:05:07 | Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates

2019-11-01 05:35:00 | [video]AbbVie Posts Stronger-Than-Expected Earnings, Lifts Forecast

2019-10-30 11:46:03 | Mylan MYL to Report Q3 Earnings: What's in the Offing?

2019-10-29 10:33:02 | Allergan AGN Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

2019-10-28 10:24:15 | RPT-UPDATE 1-Allergan settles Alzheimer's therapy lawsuit for $750 million

2019-10-28 09:00:00 | FDA Approves Medicines360's LILETTA® levonorgestrel-releasing intrauterine system 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any Hormonal IUDs

2019-10-28 08:42:00 | Allergan to book $750 million pre-tax charge in Q3 after settlement of Navenda class-action suit

2019-10-28 08:31:00 | Forest Resolves Antitrust Class Action Litigation with Direct Purchasers of Namenda

2019-10-27 19:46:00 | China could quickly become the world’s largest antidepressant market, but hurdles remain

2019-10-25 11:10:03 | What's in the Cards for AbbVie ABBV This Earnings Season?

2019-10-25 10:28:09 | Allergan Finance, LLC -- Moody's assigns Baa2 to AbbVie's exchange note offering

2019-10-25 10:10:02 | Will Allergan AGN Beat Estimates Again in Its Next Earnings Report?

2019-10-25 08:11:00 | AbbVie Announces Commencement of Exchange Offers and Consent Solicitations for Allergan Notes

2019-10-25 07:00:00 | Allergan Declares Fourth Quarter 2019 Cash Dividend of $0.74 Per Ordinary Share

2019-10-24 07:30:00 | FDA Approves BOTOX® onabotulinumtoxinA for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy